Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Nestle S.A.
Headquarters: Vevey, Switzerland
Website: http://www.nestle.com
Year Founded: 1866
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Nov 20, 2024
Product Development
Biotechs now match pharma for FDA approvals
Half of FDA approvals are sponsored by biotechs; almost all are marketing in the U.S. themselves
BioCentury | Nov 8, 2024
Deals
With Eylea rival in clinic, once-stealthy Kalaris finds public path via merger
Samsara-backed start-up launched by former Genentech colleagues picks AlloVir as vehicle to reach NASDAQ
BioCentury | Sep 4, 2024
Finance
Light from the IPO window
Six recent filings may mean appetite for new listings is on the rise
BioCentury | Aug 14, 2024
Deals
Deals Report: Pair of Merck deals in APAC region; Recursion and Exscientia merging
Plus: Denmark-based Pharmacosmos buys G1, obtaining myelosuppression drug
BioCentury | Jun 10, 2024
Deals
Deals Report: Elsie, Seres, Marengo build on existing deals to enter new ones
Plus: A takeout offer for Vanda and an ADC deal for ArriVent and Alphamab
BioCentury | Feb 20, 2024
Emerging Company Profile
EraCal: fishing for new obesity targets
Swiss company’s zebrafish platform identifies new appetite suppressant targets without unwanted adverse effects
BioCentury | Feb 2, 2024
Management Tracks
New CFOs for Sanofi, Takeda
Plus: NextPoint names Eisai vet Cheung CEO, Love joins Gilead board and updates from Acumen, Maxion, EnteroBiotix, Remix
BioCentury | Sep 11, 2023
Deals
Sept. 11 Quick Takes: Surprise miss for Acelyrin in hidradenitis suppurativa
Plus: Moderna, Immatics in oncology discovery, development deal, and updates from Takeda, Novartis, Crinetics, Verona, Nestlé
BioCentury | Dec 13, 2022
Management Tracks
Roche’s Anderson to depart
Plus: Perreault retires as McKenzie becomes CEO at CSL, and updates from Wren and OptiNose
BioCentury | Dec 1, 2022
Regulation
Nov. 30 Quick Takes: Ferring’s Rebyota wins FDA approval
Plus: Novo, Lyfe lead iECURE’s new round and updates from bluebird-argenx, Nimbus, Oncorus and more
Items per page:
1 - 10 of 173